KOL Engagement in Pharma: A Practical Guide for 2027

KOL engagement is how pharma, biotech and medical device companies work with key opinion leaders: the clinicians and researchers other healthcare professionals trust. Done well, it brings real expert insight into your strategy and credible peer education to your market. Done badly, it wastes budget, frustrates experts and creates compliance risk.

This guide walks through how to plan, run and measure KOL engagement in 2027, step by step. If you need the basics first, start with our explainer on what a KOL is in pharma.

What is KOL engagement?

KOL engagement covers every planned, contracted interaction between a company and a key opinion leader. The most common forms are:

Advisory boards: small groups of experts give feedback on data, trial design or strategy.
Consulting: one-to-one expert advice on a defined question.
Speaker programs: KOLs present approved content to other HCPs.
Research: KOLs act as investigators or authors.
Congress activity: KOLs chair symposia or present data at medical meetings.

Two teams usually own this work. Medical affairs leads scientific exchange: advisory boards, research and unsolicited scientific questions, often through medical science liaisons. Commercial teams run promotional speaker programs. Keeping the two separate is a core part of medical affairs KOL engagement, because the rules are different for each.

Why KOL engagement needs more care in 2027

Two things have raised the stakes.

Payments are public. Every applicable payment to a covered recipient is reported to CMS Open Payments, subject to the rule’s exclusions, and anyone can look it up. Program Year 2025 data, published in July 2026, showed $14.67 billion in total payments (PALTmed summary). Program Year 2026 data is due by 31 March 2027 (42 CFR 403.908). If a KOL’s payments look out of line with the work they did, it shows.

Enforcement continues. In May 2026, Takeda agreed to pay $13.67 million to resolve allegations about its speaker programs, without admitting liability (DOJ). In April 2025, Gilead agreed to pay $202 million to settle allegations that it used speaker programs to pay kickbacks (HHS-OIG). KOLs are often the speakers in these programs.

None of this means engaging less. It means engaging with a clear purpose and a clean record.

How to build a KOL engagement plan, step by step

A good KOL engagement plan answers six questions in order.

What do we actually need? Start with the medical or business question, not the names. Do you need input on a trial design? Peer education ahead of a launch? Help reading new data? The PhRMA Code, which is voluntary but widely adopted, says a bona fide consulting arrangement needs “a legitimate need for the consulting services” that “has been clearly identified in advance” (PhRMA Code, Section 6).
Who are the right experts? Map KOLs against that need. Look at clinical expertise, publications, trial experience, guideline work, teaching skill and geography. Mix national experts with regional and community physicians who are trusted locally. Medical and compliance teams should make the final choice, not sales. Our guides to KOL identification and selecting KOLs for speaker programs go deeper.
Which type of engagement fits? Match the activity to the need. Each one is reported differently in Open Payments:

Engagement	Main purpose	Usual owner	Open Payments category
Advisory board	Expert insight on data or strategy	Medical affairs	Consulting fee
One-to-one consulting	Advice on a defined question	Medical or commercial	Consulting fee
Promotional speaker program	Peer education on approved content	Commercial	Compensation for non-consulting services
Research	Clinical trials and studies	Clinical / medical	Research
Meals and travel during any of the above	Logistics	Whoever runs it	Food and beverage; Travel and lodging

Category names are from CMS. Confirm the right category for each payment with your compliance team.

How do we contract and pay? Use a written agreement that spells out the services, and pay fair market value for the KOL’s time and expertise. The PhRMA Code says compensation “should be reasonable and based on fair market value.” Set FMV tiers once, apply them consistently, and keep the rationale on file. See our guides to negotiating speaker agreements and processing honoraria.
How do we support them? KOLs are busy. Give them clear briefs, approved materials and easy logistics. Brief speakers on the approved deck and on what to do with off-label questions. Handle travel, venues and payments so they can focus on the science. Our guide to the speaker briefing process covers training, and pharmaceutical event management covers the logistics.
How do we record and report it? Log every engagement and every transfer of value as it happens, against the KOL’s record. Then the Open Payments report is a check, not a scramble. Our guide to Sunshine Act reporting explains the requirements.

Planning a launch? Our KOL engagement strategy for product launch applies these steps to the months before and after approval.

KOL management: running relationships all year

KOL management is the ongoing work of keeping these relationships organized, fair and useful. Most problems come from scattered records: contracts in email, payments in finance, feedback nowhere.

Good KOL management means:

One record per KOL. Expertise, contracts, FMV tier, past engagements, payments and feedback, all in one place.
Annual caps. Set a limit on engagements or spend per KOL, and check it before every new contract.
No overuse. Spread work across your experts. Leaning on the same few people looks bad and limits the insight you get.
Proof that you used the work. The PhRMA Code expects the company to keep “records concerning” the services and to make “appropriate use” of them. Write down what each advisory board told you and what you did with it.
Regular reviews. Once a year, check credentials, exclusion lists, FMV rates and whether each relationship still meets a real need.

What to look for in KOL management software: profiles linked to contracts and payments, cap checks, approval workflows, an audit trail, and reports ready for Open Payments. Our guide to speaker management software covers the same features from the speaker program side.

KOL engagement compliance checklist

Use this before any KOL engagement. It follows the six factors in Section 6 of the PhRMA Code, plus the speaker program rules most companies apply.

A written contract describes the services.
A legitimate need was identified in advance.
Selection criteria relate directly to that need.
You’re not retaining more experts than you reasonably need.
You keep records of the work and actually use it.
The venue and setting suit the work.
Pay is reasonable and at fair market value.
Speaker programs use approved content, modest venues and no alcohol (PhRMA Code, Section 7), and avoid repeat attendance on the same topic.
State rules are checked. See our state-level compliance roadmap.
Every transfer of value is recorded for Open Payments.

For the enforcement view, read our summary of the OIG Special Fraud Alert and our PhRMA Code guide.

How to measure KOL engagement

Measure whether the engagement delivered what you needed:

Insight used: how many advisory board recommendations changed a plan or decision.
Education quality: attendee ratings and questions at KOL-led programs.
Reach: how many relevant HCPs heard approved education, by region and specialty.
Relationship health: KOL satisfaction, renewals and response times.
Cost: spend per engagement against your budget benchmarks.

Don’t measure a KOL’s value by what they prescribe, and don’t choose speakers based on it. The OIG lists that among its warning signs.

Common KOL engagement mistakes

Starting with names, not needs. You end up paying for meetings with no clear purpose.
Letting sales pick the experts. It’s a red flag, and it usually gives you the wrong experts.
No caps. A few KOLs get most of the work and most of the money.
Advisory boards that lead nowhere. If nothing changes after the meeting, it’s hard to show the need was real.
Records in five places. This makes reporting slow and audits painful.

How ZHM supports KOL engagement

ZHM helps life sciences teams run KOL engagement without the admin. Our team handles KOL contracting, speaker programs, advisory meetings and the logistics behind them, through speaker bureau management and pharmaceutical event management.

Our platform, Zvent.ai, keeps each expert’s contracts, engagements and payments in one record, with approvals, an audit trail, and Sunshine Act and Open Payments-ready reports. Learn more about our HCP engagement platform, or see the bigger picture in our guide to HCP engagement strategies.

See how we worked with Verrica Pharmaceuticals in our case study, or try Zvent.ai free.

This article is general information, not legal advice. Talk to your compliance and legal teams about how these rules apply to your programs.

KOL engagement FAQ

What is KOL engagement?

KOL engagement is how life sciences companies work with key opinion leaders through advisory boards, consulting, speaker programs, research and congress activity.

What’s the difference between a KOL and an HCP?

Every KOL is an HCP, but few HCPs are KOLs. A KOL is an HCP whose expertise and reputation influence how peers practice.

Who should manage KOL engagement: medical or commercial?

Both, with clear lines. Medical affairs leads scientific exchange and advisory boards. Commercial leads promotional speaker programs. Compliance oversees both.